We’d love to hear your feedback on this activity. It helps us to continually improve our products.
Professor Sara Hurvitz (David Geffen School of Medicine at UCLA, Los Angeles, CA, USA) discusses her presentation at the San Antonio Breast Cancer Symposium 2021 on the aims, efficacy and safety findings of the coopERA study. Questions 1. What is giredestrant, and what is the rationale for its use in HR+, HER2− early breast cancer? […]
Professor Sara Hurvitz (David Geffen School of Medicine at UCLA, Los Angeles, CA, USA) discusses her presentation at the San Antonio Breast Cancer Symposium 2021 on the aims, efficacy and safety findings of the TRINITI-1 study. Questions 1. What are the major unmet needs in the treatment of women with HR+, HER2− breast cancer? 00:12-02:06 […]
We were delighted to catch up with editorial board member Prof Elias Jabbour (MD Anderson Cancer Center, Houston, TX, USA) to discuss his presentation at the American Society of Hematology (ASH) Annual Meeting on dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia from the PACE and Optic trials. Questions 1. What […]
We were delighted to catch up with touchONCOLOGY editorial board member Professor Robin Foà (Sapienza University of Rome, Italy) to discuss his educational session at the 63rd ASH Annual Meeting & Exposition on measurable residual disease in the management of many haematological malignancies. (PART THREE) Questions 1. What is the current role of measurable residual […]
We were delighted to catch up with touchONCOLOGY editorial board member Professor Robin Foà (Sapienza University of Rome, Italy) to discuss his educational session at the 63rd ASH Annual Meeting & Exposition on measurable residual disease in the management of many haematological malignancies. (PART TWO) Questions 1. Could you give us a brief overview of […]
We were delighted to catch up with touchONCOLOGY editorial board member Professor Robin Foà (Sapienza University of Rome, Italy) to discuss his educational session at the 63rd ASH Annual Meeting & Exposition on measurable residual disease in the management of many haematological malignancies. (PART ONE) Question What are the take-home messages from your educational session […]
We were delighted to catch up with Dr Manali Kamdar (University of Colorado, Boulder, CO, USA) to discuss the results of the randomized phase III TRANSFORM study of lisocabtagene maraleucel CAR-T cell therapy versus standard of care chemotherapy followed by ASCT in patients with relapsed or refractory large b-cell lymphoma. Question Please can you summarise […]
Dr Andreas Charalambous discusses his hopes and priorities for his tenure as President of the European Cancer Organisation, beginning in January 2022. Questions 1. What do you hope to accomplish during your tenure as president of the European Cancer Organisation? (00:27-02:18) 2. What will be your immediate priorities as president? (02:18-05:06) Speaker Disclosure: Andreas Charalambous […]
We were delighted to catch up with Dr Andreas Charalambous, President-Elect of the European Cancer Organisation, to discuss the main challenges to cancer care in Europe in the next 5 years. Speaker Disclosure: Andreas Charalambous has no financial or non-financial conflicts of interest to declare in relation to this video. Support: Interview and filming supported […]
Get the latest clinical insights from touchONCOLOGY